Hormonal
Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 25.3%) by acting as a dual GLP-1 and GIP receptor agonist.
Tirzepatide is a weekly injectable medication that mimics two gut hormones (GLP-1 and GIP) to regulate appetite and metabolism. Clinical trials show it can lead to up to 25% body weight loss, significantly outperforming placebo. It requires a prescription and ongoing medical supervision, and discontinuation leads to weight regain.
Tirzepatide is the first polypeptide to act as both a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist... The results showed dose-dependent weight loss: an average reduction of 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg... Over the entire study period, the tirzepatide group achieved a total weight reduction of 25.3%...
Why this rating
Based on multiple large, randomized, double-blind, placebo-controlled trials (SURMOUNT-1, 2, 3, 4).
Source
TRENDS IN OBESITY TREATMENT: A REVIEW OF THE LITERATURE FROM THE LAST SIX YEARS
Adam Sobiński et al. · International Journal of Innovative Technologies in Social Science · 2025
DOI 10.31435/ijitss.4(48).2025.4326
More from this paper
- Semaglutide (2.4 mg weekly) produces significant weight loss (approx. 15%) by acting as a GLP-1 receptor agonist that stimulates satiety centers in the hypothalamus.Strong
- Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) are highly effective surgical interventions for severe obesity, with RYGB showing slightly greater long-term weight loss.Strong
- Intragastric balloons (Obalon, Orbera, ReShape Duo) provide temporary weight loss (12-25% EWL) when combined with lifestyle modifications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →